Ortiz-Maldonado Gibson, ValentínRives Solà, SusanaEspañol Rego, MartaAlonso Saladrigues, A.Montoro, MercedesMagnano, LauraGiné Soca, EvaPascal i Capdevila, MarionaDíaz Beyà, MarinaCastellà Castellà, MariaCatalà, AlbertFaura, AnnaRodríguez Lobato, Luis GerardoOliver Caldés, AinaMartínez Roca, AlexandraRovira, MontserratGonzález Navarro, Europa AzucenaOrtega, Juan RamónCid Vidal, JoanLozano, MiquelGarcía Rey, EnricFernández, Sara (Fernández García)Castro Rebollo, PedroJordán García, IolandaVillamor i Casas, NeusAymerich Gregorio, MartaTorrebadell Burriel, MontserratDeyá, AngelaFernández de Larrea Rodríguez, Carlos JoséBenítez-Ribas, DanielTrias, EsteveVarea, SaraCalvo Rojas, GonzaloEsteve Reyner, JordiUrbano Ispizua, ÁlvaroJuan, ManelDelgado, Julio (Delgado González)2023-02-072023-02-072021-12-012051-1426https://hdl.handle.net/2445/193208The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Chimeric antigen receptors (CAR) targeting CD19 have shown promising results in R/R ALL, and one of these products (tisagenlecleucel) has been approved for the treatment of patients with R/R ALL up to 25 years of age.4 p.application/pdfengcc-by-nc (c) Ortiz-Maldonado, Valentín et al., 2021https://creativecommons.org/licenses/by-nc/4.0/Leucèmia limfocítica crònicaCèl·lules cancerosesTeràpia cel·lularAntígens CDImmunoteràpiaReceptors cel·lularsChronic lymphocytic leukemiaCancer cellsCellular therapyCD antigensImmunotheraphyCell receptorsinfo:eu-repo/semantics/article7188092023-02-07info:eu-repo/semantics/openAccess